Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Non-Obstructive Hypertrophic Cardiomyopathy
NCT07897500Phase 4Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Jan 2027
- Primary completion
- Jul 2029
01
Overview
Phase 4, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Dapagliflozin 10mg with Dapagliflozin Placebo (2 arms). Primary endpoint: Peak Oxygen Consumption at 24 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07897500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897500.